LLY vs NVDA
AI-powered side-by-side analysis. Updated every 2 hours.
LLY surges with FDA approval and strong 2025 growth
- • 2025 revenue rose 45% to $65.2 billion
- • Zepbound revenue $13.5 billion, up 175% YoY
- • Foundayo received FDA approval on April 1, 2026
2 signals
1 sources
Full analysis →
Nvidia's AI chip surge drives $4.6T valuation
- • Revenue surged 73% to $68 billion in last quarter
- • Market cap approximately $4.6 trillion
- • 41 out of 43 analysts rate Nvidia a buy, with average price target implying 54% upside
26 signals
5 sources
Track record: 8/14 transitions correct (5d)
Full analysis →
How This Works
The Read analyzes 50+ financial sources every 2 hours and maintains AI-scored positions on 40+ stocks. Each entity is independently evaluated based on insider activity, analyst ratings, earnings data, SEC filings, and news signals. See our track record.
This comparison updates automatically whenever either stock's analysis changes. Every prediction is timestamped and scored against real prices.
More Comparisons
Explore more